Zum Hauptinhalt springen

Buprenorphin

09. Mai 2020 | Buprenorphin

Two world first studies of depot buprenorphine completed

Two world first studies of depot buprenorphine completed Two world first studies of depot buprenorphine have recently been completed. Both studies are great achievements at the forefront of international research efforts in this field and have sali…

26. April 2020 | Buprenorphin

Progress Report on EMBED: A Pragmatic Trial of User-Centered Clinical Decision Support to Implement EMergency Department-Initiated BuprenorphinE for Opioid Use Disorder.

Progress Report on EMBED: A Pragmatic Trial of User-Centered Clinical Decision Support to Implement EMergency Department-Initiated BuprenorphinE for Opioid Use Disorder. Melnick ER, Nath B, Ahmed OM, Brandt C, Chartash D, Dziura JD, Hess EP, Hollan…

26. April 2020 | Buprenorphin

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis. Andorn AC, Haight BR, Shinde S, Fudala PJ, Zhao Y, Heidbreder C, Learned SM, Fox NL, Nadipelli VR, Hassman…

26. April 2020 | Buprenorphin

Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.

Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state. Bogan C, Jennings L, Haynes L, Barth K, Moreland A, Oros M, Goldsby S, Lane S, Funcell C, Brady K. J Subst Abuse Treat. 2020 Mar;112S…

21. April 2020 | Buprenorphin

Injectable buprenorphine for opioid use disorder: Effects on 1-year recovery outcomes

Injectable buprenorphine for opioid use disorder: Effects on 1-year recovery outcomes An extended release version of buprenorphine was recently approved by the FDA to treat opioid use disorder. Prior research has revealed the short-term benefits of…

12. April 2020 | Buprenorphin

Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach.

Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach. Caulfield MDG, Brar R, Sutherland C, Nolan S. BMJ Case Rep. 2020 Mar 25;13(3…

12. April 2020 | Buprenorphin

Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone.

Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone. Elman I, Howard M, Borodovsky JT, Mysels D, Rott D, Borsook D, Albanese M. Sci Rep. 2020 Mar 27;10(1):5617. d…

Weitere Beiträge ansehen

Weitere
akutelle Informationen
zu den Themengebieten